A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination with Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease
Graft-versus-host disease (GvHD) is a serious complication that can happen after a stem cell or bone marrow transplant. It occurs when transplanted donor cells attack the patient's own healthy tissues. The standard initial treatment is steroids, but these do not always work well enough on their own. This study tests whether adding an experimental medicine called CYP-001 to standard steroid treatment works better than steroids alone for adults with high-risk acute GvHD. Half of the participants will receive CYP-001 with steroids, while the other half will receive an inactive dummy medicine (placebo) with steroids. Neither you nor your doctor can choose which group you join. Researchers will assess whether symptoms improve by Day 28 and follow participants for at least 100 days to see if benefits last and whether patients can safely reduce their steroid doses.
At a glance
What is this study about?
When someone receives a stem cell or bone marrow transplant from a donor, the new immune cells can sometimes view the recipient's body as unfamiliar. When these donor cells attack the patient's own healthy organs—such as the skin, stomach, intestines, or liver—it is known as graft-versus-host disease (GvHD). Acute GvHD is a form of the condition that typically develops quickly in the weeks or months following the transplant.
Doctors normally treat acute GvHD with powerful anti-inflammatory medicines called corticosteroids. While steroids can be helpful, they do not work well for every patient, particularly those with more severe or 'high-risk' symptoms. In addition, taking high doses of steroids over an extended period can lead to difficult side effects, including a weakened immune system, fragile bones, and an increased risk of severe infections.
This Phase II clinical trial is evaluating an experimental treatment called CYP-001. CYP-001 is designed to calm down the overactive donor immune cells and support tissue repair. Researchers want to find out whether combining CYP-001 with standard steroid therapy clears up symptoms faster and more completely than steroids alone.
If successful, this trial could provide a much-needed new option for patients coping with this life-threatening complication. It may also help doctors lower steroid doses more quickly, protecting patients from unwanted steroid side effects while supporting a healthier recovery.
Key takeaways
- Tests whether adding CYP-001 to standard steroids improves acute GvHD treatment.
- Open to adults aged 18 and over with high-risk acute GvHD following a transplant.
- All participants receive standard steroid therapy alongside either CYP-001 or a placebo.
- Researchers will check how well symptoms have cleared up by Day 28 and Day 100.
- Participation is entirely voluntary and you can leave the study at any time.
Who may be eligible?
To be considered for this study, you must be 18 years of age or older and have had a donor stem cell or bone marrow transplant. You must also have a confirmed diagnosis of acute graft-versus-host disease that your medical team considers high-risk and in need of steroid treatment.
The trial is open to men and women of all backgrounds. However, you may not be able to join if you have certain active, uncontrolled infections, severe organ damage not caused by GvHD, or if you have already tried several other intensive treatments for GvHD that have not worked.
Your hospital transplant team will perform detailed health checks, including blood tests and physical examinations, to confirm whether taking part is safe and medically appropriate for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have received a donor stem cell or bone marrow transplant.
- I have been diagnosed with acute graft-versus-host disease (GvHD).
- My medical team has classified my GvHD as high-risk.
- I am eligible to receive corticosteroid treatment.
What does participation involve?
If you join the study, a computer system will randomly assign you to one of two groups. One group receives the experimental drug CYP-001 along with standard steroid treatment. The other group receives an inactive dummy treatment (a placebo) along with standard steroid treatment. Neither you nor your medical team will know which group you are in, which ensures the results are completely fair. The study treatment is given directly into a vein through an intravenous drip. You will have regular hospital assessments, blood tests, and checks on your skin, gut, and liver. Researchers will monitor you closely during the first 28 days to measure your early response. Follow-up visits will continue through Day 60, Day 100, and beyond to track your long-term recovery, general wellbeing, and any side effects.
Potential risks and benefits
Locations (4)
- —UnverifiedSpain
- —UnverifiedFrance
- —UnverifiedLithuania
- —UnverifiedItaly
Common questions
What is acute graft-versus-host disease?
It is a serious medical complication where transplanted donor immune cells attack the recipient's body tissues, most commonly affecting the skin, digestive tract, or liver.
What is a placebo?
A placebo is a dummy treatment designed to look just like the study medicine but containing no active drug. Comparing it against CYP-001 helps researchers see if the new medicine truly works.
Will I still receive standard treatment?
Yes. Every participant in this trial receives standard corticosteroid therapy, so no one is left without active care.
How long will I be in the study?
The main treatment and monitoring period focuses on the first 28 to 100 days, followed by periodic check-ups to track your long-term recovery.
What happens if my GvHD gets worse?
Your safety comes first. If your condition does not improve or worsens at any time, your medical team will step in immediately with alternative approved treatments.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.